Novel Approaches with HIF-2α Targeted Therapies in Metastatic Renal Cell Carcinoma by Charles B. Nguyen, Eugene Oh, Piroz Bahar, Ulka N. Vaishampayan, Tobias Else, Ajjai S. Alva

Get full text

740 Pattern of natural killer (NK) cell (CD16+CD56+) expansion correlates with response outcomes with nemvaleukin alfa treatment by Omid Hamid, Vamsidhar Velcheti, David F McDermott, Marc S Ernstoff, John L Hays, Yangchun Du, Sonali Panchabhai, Sarah Donatelli, Daniel G Smith, Ulka N Vaishampayan

726 Establishing proof of mechanism in patients: preliminary biomarker data of SRK-181 (a latent TGFβ1 inhibitor) from DRAGON Study by Minal Barve, Ahmad A Tarhini, Deepak Kilari, Randy Sweis, Timothy Yap, John Clark, Justin Gainor, Lu Gan, Ulka N Vaishampayan, Amna Sher, Yawen Ju, Susan Henry, Stephen DeWall, Asia McCune, Mo Qatanani

698 Safety and tolerability of magrolimab in combination with taxanes in patients with solid tumors by Rohit Joshi, Sylvia Adams, Jiang Shao, Wen Xu, Joanne Chiu, William Lawler, Muhammad Furqan, Ulka N Vaishampayan, Oscar Juan-Videl, Natalie Rainey, Bruno Fang, Brian Vicuna, Fadi Shihadeh, Ann Chen, Aoife Sills, Estibaliz Lopez

666 Safety, efficacy, and biomarker results of SRK-181, a latent TGFβ1 inhibitor, in anti-PD-1 resistant metastatic ccRCC patients by Minal Barve, Ahmad A Tarhini, Deepak Kilari, Rana Mckay, Randy Sweis, Timothy Yap, Justin Gainor, Raghad Karim, Lu Gan, Lan Liu, David Park, Ulka N Vaishampayan, Amna Sher, Sunil Babu, Yawen Ju, Susan Henry

718 Phase 1/2 study of PRO1160, a CD70-directed antibody-drug conjugate, in patients with advanced solid tumors and hematologic malignancies by Li Zhang, Ning Li, Brendan Curti, Stephen Spurgeon, Elisabeth Heath, Naomi Hunder, Eric Jonasch, Dingwei Ye, Zhu Chen, Melissa Reimers, Stephen Park, Weidong Li, Paolo Caimi, Ulka N Vaishampayan, Benjamin Garmezy, Swetha Kambhampati, Catherine Diefenbach, Noah Kornblum, Weili Zhao, Sharon Ma, Eric Song, Justin A Call

Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction by Pei Jye Voon, Eric X. Chen, Helen X. Chen, Albert C. Lockhart, Solmaz Sahebjam, Karen Kelly, Ulka N. Vaishampayan, Vivek Subbiah, Albiruni R. Razak, Daniel J. Renouf, Sebastien J. Hotte, Arti Singh, Philippe L. Bedard, Aaron R. Hansen, S. Percy Ivy, Lisa Wang, Lee-Anne Stayner, Lillian L. Siu, Anna Spreafico

Get full text

Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database by Gabriella Del Bene, Fabio Calabrò, Diana Giannarelli, Elizabeth R. Plimack, Lauren C. Harshman, Evan Y. Yu, Simon J. Crabb, Sumanta Kumar Pal, Ajjai S. Alva, Thomas Powles, Ugo De Giorgi, Neeraj Agarwal, Aristotelis Bamias, Sylvain Ladoire, Andrea Necchi, Ulka N. Vaishampayan, Günter Niegisch, Joaquim Bellmunt, Jack Baniel, Matthew D. Galsky, Cora N. Sternberg

Get full text

Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy by Karen A. Autio, Emmanuel S. Antonarakis, Tina M. Mayer, Daniel H. Shevrin, Mark N. Stein, Ulka N. Vaishampayan, Michael J. Morris, Susan F. Slovin, Elisabeth I. Heath, Scott T. Tagawa, Dana E. Rathkopf, Matthew I. Milowsky, Michael R. Harrison, Tomasz M. Beer, Arjun V. Balar, Andrew J. Armstrong, Daniel J. George, Channing J. Paller, Arlyn Apollo, Daniel C. Danila, Julie N. Graff, Luke Nordquist, Erica S. Dayan Cohn, Kin Tse, Nicole A. Schreiber, Glenn Heller, Howard I. Scher

Get full text